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ABSTRACT
Enzymes are biological catalysts, and they accelerate reactions by lowering the
activation barrier. In nature, enzymes have been optimized by natural selection
and possess precise three-dimensional active sites. With these active sites, they
can typically catalyze reactions with high efficiency and specificity. Compared to
traditional catalysts, enzymes are generally more environmentally friendly, and they
can catalyze reactions in water and at ambient temperature and pressure. However,
native enzymes are usually only well suited for a restricted range of substrates and
are limited in the types of reactions they perform. The Arnold lab has recently
focused on endowing enzymes with the ability to catalyze new-to-nature reactions
through directed evolution. Here, we present a set of enzymes engineered for
the ability to insert a lactone carbene into B–H, C–H, and N–H bonds with high
yield and enantioselectivity. B–H insertion is achieved by engineered cytochrome
c enzymes, while N–H and C–H insertions are achieved by engineered cytochrome
P450 enzymes. With this work, we expand nature’s toolbox for lactone insertion
chemistry. Since lactones are highly bioactive, these engineered enzymes could be
powerful tools in the synthesis of a range of pharmaceuticals and natural product
targets.
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C h a p t e r 1
INTRODUCTION
1.1 Directed Evolution of Enzymes
Directed evolution emerged in the 1990s as a way to engineer proteins with en-
hanced natural and new-to-nature properties.1 To improve the natural functions of
an enzyme, directed evolution has been used to introduce and increase thermo- or
solvent stability, improve activity on natural substrates, and expand substrate speci-
ficity/scope. In recent years, directed evolution has also been used to endow proteins
with the ability to perform entirely new reactions. Developed primarily by Frances
Arnold at Caltech in response to the difficulty of predicting protein function based
on its sequence, directed evolution is a robust and reliable way to tailor complex
proteins for a specific function.2 To some extent, directed evolution mimics natural
selection in an experimental setting. Researchers create gene libraries of variants of
a “parent” protein, express these variants, screen for a desired function, and select
the one with the highest activity. The gene coding for the best variant is used as the
“parent’ in a subsequent round. This iterative process is repeated until the desired
functionality is achieved (Figure 1.1).
2
Figure 1.1: An overview of the process of directed evolution. Through an itera-
tive process of mutagenesis and screening, proteins can be optimized for desired
functions.
Directed evolution has been applied to the engineering of a diverse range of pro-
teins including antibodies,3 biotechnology tools such as CRISPR-Cas proteins for
genome editing,4 genetic circuits5 and biocatalysts.6 Biocatalysts are the focus of
the research in the Arnold lab. Enzymes have risen to prominence in performing
chemical transformations because they can have high efficiency and exquisite selec-
tivity, enabled by their tunable three-dimensional active sites, while reducing the
environmental hazards produced. In addition, they are genetically encoded and can
be expressed in microbes such as Escherichia coli. They rely on earth-abundant
metals such as iron or zinc, and they can conduct reactions at ambient temperature
and pressure.7 Due to these advantages, among others, enzymes have been slowly
taking over some of the niche occupied by traditional transition metal catalysts.8,9
Since naturally occurring enzymes are typically limited in scope, there is need for
researchers to engineer variants for diverse applications.
1.2 The Evolution of Enzymatic Carbene Transferases
In 1999, the Arnold lab started engineering cytochromes P450, which naturally per-
form oxidative chemistry such as hydroxylation.10 Researchers in the group focused
on expanding the scope of the oxidation chemistry of cytochromes P450 to novel
substrates including steroids,11 small alkanes such as ethane,12 and alkenes (via
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epoxidation).13 They also worked on engineering other properties of the enzymes,
such as their tolerance to organic co-solvents.14 In the last decade, researchers in
the Arnold group took a chemomimetic approach and discovered the ability of engi-
neered cytochromes P450 to perform carbene and nitrene transfer reactions, which
proceed through iron-carbenoid and iron-nitrenoid intermediates.15 This resulted
in the introduction of a wide range of new-to-nature chemistry catalyzed by cy-
tochromes P450. Some remarkable, recently developed carbene transfer reactions
performed by engineered P450s include stereodivergent cyclopropanation,16 bicy-
clobutane formation,17 cyclopropenation of internal alkynes,18 and enantioselective
carbene C–H insertion19 (Figure 1.2).
Figure 1.2: A selection of carbene-transfer reactions catalyzed by cytochromes P450
developed by the Arnold lab. These enzymes furnish cyclopropanes from alkenes
(1.2), bicyclobutanes from alkynes (1.4), cyclopropenes from internal alkynes (1.5),
and new C–C bonds from C–H bonds (1.3).
It is posited that these new-to-nature reactions proceed through an iron-carbenoid
intermediate instead of the naturally occurring iron-oxo intermediate (Figure 1.3).
4
Figure 1.3: An iron-oxo intermediate enables the natural oxidation chemistry of
heme proteins (left). The posited intermediate for heme-dependent carbene transfer
reactions replaces the iron-oxo intermediate with an iron-carbenoid intermediate
(right), enabling the introduction of carbon into organic reactants.
A key development that enabled these oxidative enzymes to perform carbene transfer
reactions was the mutation of the axial ligand from cysteine to serine (Figure 1.4),
resulting in a new enzyme, which was named cytochrome P41120 (due to the change
in the peak of the Soret band of CO-bound protein from 450 nm to 411 nm). This
axial serine ligation has enabled a more diverse array of chemistries. In the natural
oxygenation chemistry, the iron is in a low spin Fe(III), which transitions to the
high spin state when the substrate binds. At this point, the reduction potential shifts
where it can be endogenously reduced to Fe(II), at which point oxygen can bind.
Among other effects, the serine axial ligand increases the reduction potential of the
low spin state, allowing the heme cofactor to be reduced by endogenous NADPH
and disfavoring oxygenation chemistry.
Figure 1.4: The porphyrin complex of a P411 variant, with the defining serine heme
ligation. This axial ligand promotes carbene transfer reactions by increasing the
reduction potential of the low spin state, among other effects.
The Arnold lab has also developed carbene transfer reactions using cytochrome c
enzymes. These enzymes are found in prokaryotes and are a part of the electron
transfer chain in the mitochondria of eukaryotes. Using cytochrome c enzymes
derived fromRhodothermus marinus theArnold lab has focused on carbene insertion
reactions with less explored heteroatoms such as boron21 and silicon22 (Figure
5
1.5). The lab began working with engineered cytochrome c enzymes when a
wild-type cytochrome c was found to catalyze an Si–H insertion reaction with
high enantiomeric excess. This was intriguing because cytochrome c does not
possess a known catalytic function in nature.23 Furthermore, the cytochrome c
from Rhodothermus marinus was chosen because of the thermophilic nature of
this organism. This protein is quite thermostable, with a Tm of 106 ± 3°C.24 A
thermostable engineering starting point will be able to tolerate more destabilizing
mutations than a more unstable parent protein.25
Figure 1.5: A selection of carbene transfer reactions catalyzed by engineered cy-
tochrome c enzymes. These engineered enzymes form C–Si (1.7) and C–B (1.8)
bonds, introducing nature to the ability to produce organosilanes and organoboranes.
The Fasan lab has developed myoglobin-based carbene transferases to perform —
among other reactions — intramolecular cyclopropanation26 and S–H insertion.27
Meanwhile, the Hartwig lab has used artificial metalloenzymes with an iridium-
porphyrin cofactor to perform C–H insertion reactions.28
In all, the Arnold lab, and others,29 have been able to demonstrate that enzymes can
act as carbene transferases. The lab maintains an interest in further developing and
expanding the platform of carbene transferases because of their general synthetic
utility.
1.3 Brief Background on Lactones
This thesis will focus on reactions with lactones. Lactones are cyclic esters. Six-
and five-member lactones, known as X-lactones and W-lactones respectively, are the
most common due to ring strain minimization.30 Synthesis of lactones are rather
well described. Aside from the simpler lactonization of hydroxy esters, a variety of
methods have emerged. These include iodolactonization,31 Yamaguchi lactoniza-
tion,32 Baeyer-Villiger oxidation,33 and ring closingmetathesis.34 The extent that the
synthesis of lactones has been developed highlights the utility of these compounds.
In this work, we do not focus on the formation of lactones, rather on intermolecular
reactions of lactones.
6
One attractive property of lactones, particularly W- and X-lactones, is their bioac-
tivity.35 Compounds such as damsin, ambrosin, and cnicin have shown antimicro-
bial properties. Other lactones have anti-inflammatory properties. Spironolactone
and Eplerenone (marketed under Inspra®) are common antihypertensive pharma-
ceuticals. Lactone-bearing compounds have also shown efficacy against cancer.
Camptothecin and its derivatives are treatments for breast, colon, and lung cancers,
among others. Etoposide has been used in leukemia, lung cancer, and testicular can-
cer treatment. Costunolide and related compounds have been employed against brain
cancers and leukemias. Outside of medicine, lactone-bearing compounds have been
used in perfumes (X-dodecalactone and X-decalactone), flavoring agents for food (5-
ethyl-W-lactone and cis-3-methyl-4-octanolide), and insecticides (flupyradifurone).
Figure 1.6 summarizes some applications of lactone bearing compounds.
Figure 1.6: A selection of lactone bearing compounds and their applications. Most
of these contain stereocenters, underscoring the importance of enantioselective
methods.
Lactones are prochiral and most of the compounds in Figure 1.6 bear stereocenters.
Thus, in the synthesis of lactone containing pharmaceuticals, it is critical to apply
enantioselective methods to maximize potency and avoid unwanted side effects.36
7
In addition to these discovered lactone-bearing compounds, it is likely that there are
plenty of uncharacterized compounds that have the potential to be medicinally or
industrially important.
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C h a p t e r 2
LACTONE CARBENE B–H INSERTION
2.1 Project Inspiration
Synthesis of chiral organoboranes is of interest to synthetic and medicinal chemists.
Organoboranes serve as useful intermediates in pharmaceutical syntheses in part
because of the variety of methods developed for manipulation of these compounds.
The most notable of these is Suzuki coupling.37 In addition, organoboranes have
shown bioactivity as antibacterial, antidiabetic, anticoagulant, antiviral, and even
antitumor agents.38 Transition metal catalyzed reactions for chiral organoborane
formation through carbene insertion chemistry have been developed, primarily using
rhodium catalysts.39
Discussed inChapter 1, theArnold lab has previously developedRhodothermus mar-
inus cytochrome c variants to insert methyl-EDA into B–H bonds. We wanted to
expand the capability for laboratory-evolved enzymes to synthesize chiral organob-
oranes with lactones. In addition to the increased steric bulk, these cyclic carbenes
have completely different geometric configuration in the active site, with a small
dihedral angle d(Fe-C-C-O)(< 13°). Subsequently, their electronic states are quite
distinct from the states of linear carbenes1. Expanding the enzymatic scope to
these lactones would be another tour-de-force of the capabilities of evolved en-
zymes. Furthermore, lactones are generally incompatible with the aforementioned
rhodium catalysts due to V-hydride elimination,40 necessitating new methods. We
investigated five-, six-, and seven-membered lactones for this chemistry. As our
model reaction, we set out to evolve an enzyme to catalyze the reaction between an
N-heterocyclic carbene (NHC) protected borane (2.1) and the 5-membered lactone
(2.2) with high yield and enantioselectivity (Figure 2.1).
1These conclusions were found via a computational density functinal theory (DFT) study con-
ducted by collaborators on this work, Shuo-Qing Zhang and Dr. Xin Hong
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Figure 2.1: The model reaction for the expansion for carbene B–H insertion chem-
istry to cyclic carbene precursors. Reactions were set in M9-N, under anaerobic
conditions, with 10 mM substrate loading.
2.2 Previously Conducted Enzyme Optimization
Other members of this project, Dr. Kai Chen, Dr. Xiongyi Huang, and Dr. S.B.
Jennifer Kan began by screening a range of Rma cytochrome c variants, including
those used to perform the previously developed borylation reactions in the Arnold
lab, for the reaction between 2.1 and 2.2. Fascinatingly, they found that wild-
type cytochrome c could catalyze this reaction with 960 TTN, but with insufficient
enantiomeric excess (34%). They then continued the search for variants that would
improve the selectivity of this enzyme. They uncovered an M100D mutation, which
was beneficial for both the B–H and Si–H insertion chemistry. While it improved
the activity to 1280 TTN, it did not affect the selectivity. Site-directed mutagenesis
at residue V75 revealed a V75R mutation which improved the total turnovers to
1640 TTN and the enantioselectivity to 87%. An M103V mutation increased the
selectivity, though at the cost of the yield, resulting in a variant with 90% ee,
and 1270 TTN. To further improve the enantioselectivity, they then considered
conducting site-saturation mutagenesis at sites within 10 Å of the iron center in the
wild-type Rma cyt c (Figure 2.2).2
2This figure is reproduced from the following published work:
Chen, K.; Huang, X.; Zhang, S-Q.; Zhou, A.Z.; Kan, S.B.J.; Hong, X.; Arnold, F.H. Engineered
Cytochrome c-Catalyzed Lactone-Carbene B–H Insertion, Synlett 2019, 30, 378-382.
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Figure 2.2: The active site of wild-type Rma cyt c, which was used to guide the
choice of future residues to mutate. The selected residues are highlighted. (PDB:
3CP5)24
They formed a double site-saturation mutagenesis library via the 22-codon trick
at positions M99 and T101,41 since these sites reside on the front loop, which is
suspected to be important in the overall active-site structure. Indeed, they identified
a doublemutant (M99QT101Y), which improved the enantioselectivity even further
(93% ee), though this did drop the activity (970 TTN). (Figure 2.3). This led to
the final variant, BORLac, which had five mutations from the wild-type Rma cyt c
(V75R M99Q M100D T101Y M103V).
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Figure 2.3: The TTN (bars) and enantiomeric excess (line) of variants that we
identified in our lactone carbene B–H insertion lineage. Data collected by co-
authors in the Arnold lab.
2.3 Substrate Scope
At this point, I joined the project. We examined the substrate scope of our final
variantBORLac. First, we experimentedwith different substituents on the stabilizing
NHC group (Figure 2.4) in reactions with 2.2. We found that variant BORLac could
achieve good yield and selectivity with electron withdrawing (2.4b), alkyl (2.4a,
2.4c, 2.4d), and bulky (2.4d) substituents on the NHC group.
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Figure 2.4: The scope of variant BORLac with 5-membered lactones and NHC-
borane derivatives.
We then wanted to challenge our enzyme with 6-member lactones. Despite the
increased steric bulk, we found that BORLac could accept this substrate with high
yield (up to 98%) and selectivity (up to 92% ee) (Figure 2.5). As with the 5-
membered lactone, the enzyme could tolerate electron withdrawing (2.5c) and ethyl
(2.5b) substituents.
Figure 2.5: The scope of variant BORLac with 6-membered lactones and NHC-
borane derivatives.
To further test variantBORLac, we assessed 7-membered lactone derivatives, which,
despite bearing a ring being just one carbon larger than the 6-membered lactone,
could only yield a product with less than 50 TTN (Figure 2.6). However, we
speculate that with further evolution, we would be able to craft an active site with
a different electronic environment, which would allow for efficient formation of the
7-membered lactone product, 2.6.
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Figure 2.6: The efficacy of variant BORLac with 7-membered lactones is limited.
2.4 Conclusion
We developed an enzymatic variant, Rma cyt c BORLac, which is capable of in-
serting lactones into NHC stabilized B–H bonds. BORLac is compatible with 5-
and 6-membered lactones and NHC stabilized boranes with electron-donating and
electron-withdrawing substituents. Overall, this project is an expansion of previ-
ous work in the Arnold lab to structurally more complex substrates and further
demonstrates the applicability of evolved enzymes in performing challenging car-
bene transfer reactions enantioselectively. To the best of our knowledge, this method
is the first demonstration of an intermolecular carbene transfer reaction for the syn-
thesis of chiral organoboranes bearing bioactive lactone motifs.42 Furthermore, we
demonstrate that hemeproteins can circumvent problematic side pathways such as
V-hydride migration. This provides a basis for studies on future enzymatic lactone
insertion reactions.
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C h a p t e r 3
LACTONE CARBENE C–H INSERTION
3.1 Conception and Basis for Reactivity
In 2019, the Arnold lab made a breakthrough in repurposing cytochrome P411s by
engineering an enzyme that could perform enantioselective carbene C–H insertion,
as discussed in Chapter 1.2. In this reaction, the Arnold lab used an engineered
cytochrome P411 to insert a diazoacetate, 3.2, into C–H bonds with high enantios-
electivity and total turnovers (Figure 3.1).
Figure 3.1: Previously developed carbene C–H insertion reaction by the Arnold lab
using an evolved cytochrome P450 variant. This is the first instance of carbene C–H
insertion using an earth-abundant iron center. The enzyme was optimized for linear
carbene precursors.
To further expand this chemistry, we set out to train cytochrome P411s to selectively
catalyze carbene C–H insertion using cyclic carbene precursors such as lactones.
The lactonemotif adds a stereocenter to the product at the U-position, opening up the
possibility of creating products with contiguous U- and V-chiral centers. This makes
stereoselective synthesis an interesting and challenging endeavor. Furthermore, the
lactone is a privileged motif in pharmaceuticals, making the ability to manipulate it
potentially relevant to medicinal chemists.43
There are transition-metal catalysts that can perform similar carbene insertion
chemistries,44,45 such as dirhodium46 and iridium47 catalysts. However, in addi-
tion to being less sustainable and sometimes limited in selectivity, transition metal
catalysts have shown fewdemonstrations ofC–H insertion of acceptor-only carbenes,
particularly those bearing U-alkyl substituents due to competition with V-hydride
migration.40 We found success in circumventing this V-hydride migration pathway
in our previously completed lactone B–H insertion project. Thus, we hypothesized
that using a cytochrome P450 variant we would be able to avoid side reactions
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and form chiral products, including those with contiguous chiral centers, with high
stereoselectivity (Figure 2.2)
Figure 3.2: A generalized scheme of the developed enzymatic reactions. The
proposed enzyme would be able to exert stereo control on two contiguous chiral
centers while circumventing side with V-hydride migration pathways.
3.2 Identifying the Best Variant
We began our studies by screening a diverse library of cytochrome P411 and cy-
tochrome c variants for activity in performing U–amino C–H insertion using 4,N,N
trimethylaniline (3.6) and a W-lactone carbene precursor (3.5) (Figure 3.3). Reac-
tions were conducted under anaerobic conditions in E. coli expressing the P411
variants suspended in M9-N. Substrates were loaded to a final concentration of 10
mM.
Figure 3.3: The initial screening reaction identified cytochrome P411-C10 as the
most promising variant to begin the evolution, though the initial activity and se-
lectivity were quite modest. TTN was characterized by protein concentration and
reverse phase HPLC, while ee was determined by chiral HPLC.
We found that cytochrome P411-C10— a robust and versatile variant for carbene C–
H insertion reactions was the best performing variant, though it could only complete
the U-amino C–H insertion reaction with rather low TTN and enantiomeric excess
(115 TTN, 47% ee). The resulting product from this reaction bears a V-amino
lactone motif, which is the core of pharmaceutical targets such as sesquiterpene
lactone amino derivatives.
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3.3 Evolution of a Biocatalytic Platform
Launching off this starting point, we conducted site-saturation mutagenesis of the
starting P411 variant (P411-C10) with the model reaction. Harboring the enzymes
in E. coli, we targeted residues known to be proximal to the active site48 using the
22-codon trick to generate site-saturation libraries41(Figure 3.4)1
Figure 3.4: Active-site residues that were targeted by site-saturation mutagenesis.
This was based off a P411-E10 variant (pdb: 5UCW)48with homology to the starting
P411 C10 variant. Residues highlighted in blue indicate residues that had more of
an effect on the ee, while residues highlighted in orange had a greater impact on
TTN (See Figure 3.5).
We found that the first two mutations, both residing on active-site loops (T327V
and Q437L, respectively) improved the total turnover number 9-fold, and an S332A
mutation increased the activity to over 1200 TTN (Figure 3.5). However, the
enantioselectivity did not increase and it even decreased slightly from 47% to
approximately 40% ee. While enantioselectivity is usually correlated to activity due
to the optimization for the active site for a specific substrate or class of substrates,
we hypothesized that this might not be the case for our model substrate, 3.7 because
it may bind with different orientations due to its symmetric nature.
1This figure is reproduced from the following published work:
Zhou, A.Z.; Chen, K.; Arnold, F.H. Enzymatic Lactone-Carbene C–H Insertion to Build Contiguous
Chiral Centers, ACS Catal. 2020, 10, 5398-5398
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Figure 3.5: The evolutionary lineage for the reaction between 4,N,N-trimethylaniline
(3.7) and a W-lactone carbene precursor (3.8). Total turnover number is shown by
bars, and the enantioselectivity is shown by the lines. Reactions were conducted
in quadruplicate and monitored by reverse phase HPLC and chiral HPLC analysis.
L7 catalyzed the reaction with up to 2010 TTN, and L9 could catalyze the reaction
with up to 90% ee.
To evolve for selectivity, we decided to focus on residues that were previously shown
to increase enantioselectivity and selected variants based on enantioselectivity rather
than total turnover numbers. Instead of conducting TTN-based screens, we used
chiral HPLC to test for variants that improved selectivity only. After identifying
these variants, we then tested the activity in a validation experiment to ensure that
the mutation was not significantly inactivating. Once we shifted to this strategy,
we were able to increase the enantioselectivity, though sometimes this was at odds
with the TTN. Mutation A87P increased the enantioselectivity from 39% to 56% ee,
though it dropped the total turnover number. Mutating A264 to a serine resulted in
a significant boost in both enantioselectivity and TTN. When re-targeting site 327,
a mutation from valine to proline (V327) resulted in a modest boost in selectivity
(from 64.5 to 75% ee) while maintaining high activity. Interestingly, a proline
mutation was not beneficial in the initial screening at site 327 (which resulted in
variant L2), demonstrating the important effect of epistasis in directed evolution.49
Mutations E264D and V328L resulted in the final variant (L9), which had 90% ee,
but reduced activity (590 TTN). Fascinatingly, from this step in the evolution, we
identified another variant (L10), which resulted from a V328Rmutation and showed
the opposite enantio-preference (-68% ee) compared to other enzymes in the lineage.
We hypothesize that this might arise due to different carbene orientations on the
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heme center, as a leucine residue might interact more strongly with the alkyl groups
of the lactone, while an arginine residue might interact with the ester group. While
the precise mechanism of this reaction is not known, the promising result from the
L10 variant indicates the tunability of the enzyme for synthesis of diverse products.
3.4 Substrate Scope
To continue the study, we assessed the ability of our enzymes to accept diverse
substrates beyond 3.7. We focused on variants L6–L10 since they showed the
highest enantiomeric excess or TTN. We began by evaluating other primary C–H
bonds (Figure 3.6a). We tested a range of substituents on the aromatic ring including
electron donating (3.9a, 3.9c, 3.9d) and electron withdrawing (3.9b) groups. We
also tested ortho, meta, and para positions. Consistently, L9 and L10 gave the
opposite stereo preference. In addition, L9 consistently was more selective than L6
and L7, though this was not a surprise because L9 was the most selective variant
in reactions with the model substrate. The performance of the enzymes showed
some degree of substrate dependency. For instance, L10 had higher activity than
L9 for 3.9e, even though this was not the case for the model substrate. In addition,
L6 achieved the highest TTN out any of these reactions (3.9a, 2040 TTN), but also
frequently performed worse than other enzymes in selectivity (3.9c, 3.9e).
We then noticed that for 3.10, L9 and L10 demonstrated a shifting regiospecificity
(Figure 3.6b). L9 heavily favored the primary insertion product (99:1 r:r), but L10
only moderately favored the primary C–H insertion product (71:29 r:r). Not only did
this excite us because it once again showed the capability for our enzymes to be tuned
for diverse selectivities, but it also provided hope that our existing lineage could
catalyze reactions of secondary C–H bonds. This would enable the construction of
contiguous chiral centers. Moreover, we hypothesize that with further evolution, we
could favor the synthesis of 3.10b over 3.10a.
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Figure 3.6: (a) The activity and selectivity of enzymatic variants for lactone carbene
C–H insertion into primary C–H bonds. (b) Substrates with both primary and
secondary C–H bonds revealed different regioselectivity for L9 vs L10, opening up
the possibility for performing carbene insertion into secondary C–H bonds.
Exploring the potential of the enzymes for insertion into secondary C–H bonds
(Figure 3.7), we evaluated pyrrolidine, azetidine, and dialkyl-aniline derivatives.
Despite training the enzymes only on primary C–H bonds, these enzymes had very
favorable properties with regards to both activity (up to 4,000 TTN, 3.11c/L9)
and enantioselectivity (up to 99% ee, 3.11c/L9) in these reactions. This inspires
confidence that we did not over-optimize our enzyme to our model substrate, 3.7.
In general, the diastereoselectivity and enantioselectivity were good to high. In a
fascinating case, 3.11a, the samemajor diastereomer was formed with both enzymes
(L9: 94:6 d:r, L10: 99:1 d:r), but the opposite enantiomer was formed (L9: 81% ee,
L10: -94.5% ee). This trend was observed for other compounds including 3.11b. In
addition, we found that these enzymes were not too adversely affected by electron-
withdrawing (3.11e) or electron-donating (3.11d) substituents, as selectivity and
activity remained acceptably high. To test the limits of our enzymes, we tried
structurally and chemically distinct substrates such as 3.11f. With a higherC–Hbond
dissociation energy and a unique structure, we expected our enzymes to struggle to
obtain favorable selectivities and activities. Indeed, while diastereoselectivity was
high (95:5 d:r), the enantiomeric excess (13%) and activity (140 TTN) were low.
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Figure 3.7: The activity and selectivity (diastereo- and enantio-) of enzymatic
variants for lactone carbene C–H insertion into secondary C–H bonds.
3.5 Potential for N–H Insertion
While evaluating the properties of our enzymes for 3.10, we noticed the formation
of a side product, 3.10c (Figure 3.8). We hypothesized that this might arise from
an elimination reaction followed by N–H insertion. If this were the case, it would
imply that our engineered enzymes might be able to perform carbene N–H insertion,
which will be discussed in the following chapter. We are unsure why 3.10c is only
observed in reactions of this substrate. We speculate it might be caused by the
specific configuration of 3.10a, which might position the eliminated hydrogen in
close proximity of a basic residue in the active site.
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Figure 3.8: A potential mechanism to justify formation of 3.10c. Here, product from
the lactone carbene C–H insertion reaction undergoes elimination. The resulting
amine can react to give product 3.10c.
3.6 Potential Applications in Pharmacuetical Synthesis
A promising potential application of this chemistry is in the construction of amino
derivatives of sesquiterpene lactones. Sesquiterpene lactones often possess antitu-
mor or antimicrobial activities and are classified by possessing an U-methylene-W-
lactone motif, which allows them to bind to biological nucleophiles such as thiols
and shut down deleterious cells. However, these compounds are often constrained
by off-target effects and limited solubility. Researchers have found that masking the
U-methylene group with an amine alleviates these problems by improving solubility
and preventing off-target electrophilic activity (Figure 3.9). The amino derivatives
often are specific for deleterious cells, and once inside these cells, they are converted
back to the original bioactive sesquiterpene lactone.
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Figure 3.9: The conversion of sesquiterpene lactones (3.12a) to their amino deriva-
tives (3.12b) occurs in the bloodstream, enabling more favorable pharmacological
properties. Once inside cells, the compound is reverted to its original bioactive
form.
Thus, sesquiterpene lactone amino derivatives are highly valuable prodrugs with in-
credible potential in medicinal chemistry.50 Our enzymatic platform could be useful
in constructing sesquiterpene lactone amino derivatives sustainably and cost effec-
tively, especially those with aryl substituents on the amine. Figure 3.10 shows some
identified targets with the chiral V-amino lactone motif. We imagine that our enzy-
matic platform could be used to synthesize related molecules. The versatility of our
enzymes and broad substrate scope coupled with the tunability of regioselectivity
and enantioselectivity could be used to meet the needs of medicinal chemists tar-
geting these amino derivatives of sesquiterpene lactones and other pharmaceutical
targets.
23
Figure 3.10: Several known sesquiterpene lactone amino derivative prodrugs, with
the chiral V-amino lactone motif highlighted.
3.7 Conclusion
Our enzymatic platform based on a series of engineered cytochrome P411 enzymes
can catalyze lactone carbene C–H insertion to form new C–C bonds with high
efficiency — up to 4000 TTN — and good to excellent enantioselectivity, -94.5%
to 99%. Our enzyme circumvented a V-hydride migration pathway that has plagued
other catalysts attempting to perform similar chemistry. To our knowledge, this is the
first enzymatic synthesis of a chiral V-amino lactone motif. This motif is extremely
relevant to synthetic and medicinal chemistry, and our platform could be especially
useful for the construction of sesquiterpene lactone amino derivatives, among other
potential useful products. We were able to construct products selectively with
two contiguous chiral centers, and we found that a single mutation can completely
invert both centers. The same single mutation also inverted single chiral centers
and was able to affect the enzyme’s preference of primary versus secondary C–H
bonds. Furthermore, our enzymes have been shown to be quite accepting of diverse
substrates. The scope of the enzymes and their tunability enable them to meet the
needs of chemists interested in preparing diverse chiral V-amino lactones.
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C h a p t e r 4
LACTONE CARBENE N–H INSERTION
Having evolved a robust platform for carbene C–H insertion (Chapter 3), we wanted
to expand this chemistry to N–H insertion. We are interested in N–H insertion
chemistry for several reasons. Amines, owing primarily to their nucleophilicity are
active in biological systems and are found in a variety of pharmaceuticals;51,52 for
this reason, reactions to form C–N bonds are of interest for synthetic and medici-
nal chemists.53 However, both enzymatic and transition-metal enabled reactions to
enantioselectively perform N–H insertion reactions are limited.
Transition metal catalyzed methods to do such insertion reactions typically use both
a transition metal as well as a chiral proton transfer catalyst (PTC) (usually a small
molecule) to bias the product to a certain stereo fate. After the metal carbenoid is
formed, which is akin to the metal carbenoid discussed in Chapter 3, the amine will
act as a nucleophile and attack it, forming an ylide. Protonation is then guided by
the PTC to form a stereoselective product (Figure 4.1).54
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Figure 4.1: The typical strategy to perform enantioselective N–H insertion in tran-
sition metal catalyzed reactions. A chiral PTC helps ensure the enantioselective
fate. After the carbene binds to the transition metal, the insertion reaction occurs.
At this point, the transition metal is eliminated, forming an ylide intermediate. To
form an enantiopure product, the protonation must be controlled, which the chiral
PTC accomplishes.
Studies on similar reactions within a heme protein have been conducted, and they
demonstrated that the enzymatic system behaves similarly.55 While the insertion
reaction is facile—even a free heme complex can catalyze it— the enantioselectivity
remains difficult to control. Enzymes reside in protic environments (water) and have
protic amino acid residues that surround the iron porphyrin center. These make it
difficult to control the proton transfer. Therefore, to achieve these enantioselective
N–H insertion reactions, the active site must be carefully tuned to ensure that the
proton transfer, either from water or from the amino acids, occurs at the correct
orientation and correct timing (Figure 4.2). Indeed, this is quite challenging, and
there is only one reported instance of an enzyme achieving enantioselective N–H
insertion.56 In this work, the Fasan group engineered a myoglobin variant to perform
this chemistry. However, this was limited in its enantioselectivity (only up to 82%)
and restriction to linear carbenes and primary anilines.
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Figure 4.2: The posited pathway for N–H insertion within the enzymatic active site.
The dotted circle represents the enzymatic active site. Amino acid residues create
an environment than can precisely perform proton transfer to the ylide. The nature
of this proton transfer will be further discussed.
Inspired by the observation of trace amounts of an N–H insertion product during
the lactone carbene C–H insertion process, we decided to use a lactone carbene
precursor for this study. The lactone is also fascinating because of its bioactivity
and because traditional transition metal catalysts have been largely unsuccessful
with them, in part due to the control needed to prevent unwanted V-H elimination.
4.1 Identifying the Best Variant
To start our study, we screened a reaction of 4.1 and 4.2 catalyzed by hemoprotein
variants in whole cell E. coli (Figure 4.3). This screening was carried out by Dr.
Zhen Liu.
Figure 4.3: The model reaction for carbene N–H insertion reaction. The product,
4.3, is bioactive. Whole cells expressing hemeprotein variants were suspended in
M9-N. Reactions were set in a 96-well plate under anaerobic conditions (10 mM
amine, 10 mM carbene precursor, 25 mM d-glucose) and shaken overnight.
Dr. Zhen Liu screened more than 40 enzymes that were previously optimized for
carbene and nitrene reactions, including cytochrome P411 and Rma cytochrome c
variants. He assessed enzymes previously evolved for lactone insertion reactions:
P411-G8S, P411-L5, P411-L7, and Cyt c BORLac. This showed that L7, an enzyme
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from the lactone carbene C–H insertion lineage (Chapter 3) could catalyze this
reaction with 81% yield and 94% ee (Figure 4.4). Interestingly, there is another
instance of divergent enantioselectivity, as L5 (well C9) and L7 (well C10) form
opposite enantiomers, despite being only two mutations apart. Indeed, the highest
performance from enzymes derived from the carbene insertion lineage. Most other
enzymes were either limited in yield, selectivity, or both.
Figure 4.4: A heatmap demonstrating the results of the enzyme screening with some
notable wells labeled with the enzymes that reside within. P411-L7 is in well C10
and had the best properties: 81% yield and 94% ee. Figure made using Holoviews
and Python.
Seeing more evidence of the promise of the C–H insertion lineage in catalyzing this
N–H insertion reaction, we screened the entire lineage (Figure 4.5). Wehypothesized
that to further improve the enantioselectivity, it would be beneficial to improve the
stability of the enzyme to prevent the release of free heme as the enzyme degrades.
This is important since free heme forms racemic N–H insertion product. To that
end, we added back the previously truncated FAD domain to our best variant, (L7) to
give variantL7-FL. Indeed, we found that adding back this domain further improved
the selectivity and activity of the enzyme. We hypothesize that the addition of this
domain makes the enzyme more thermodynamically favorable because — having
been optimized by nature — it has minimal disfavored interactions.
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Figure 4.5: The lineage of L1-L7 and their yields (bars) and selectivities (line) in
forming 4.3. L1-L7 have the FAD domain truncated. L7-FL has the FAD domain
added back to the enzyme, resulting in a slight increase to the yield and selectivity.
It appears that the mutation from L5 to L6 (A264S) was crucial in improving the
enantioselectivity.
It appears that the A264S mutation that is added between L5 and L6 is crucial in
increasing the yield and selectivity. Based on the crystal structure of P411-E10 (as
shown in Chapter 3), this residue resides directly above the active site and is the
closest in proximity to the reaction. It is not surprising that thismight be promising in
promoting this carbene transfer reaction and in guiding the stereoselectivity during
the proton transfer step. In an experiment conducted by Dr. Zhen Liu, it was
confirmed that the serine mutation was able to much better facilitate high yield and
selectivity compared to other amino acids (including those with similar properties
such as threonine and cysteine).
4.2 Substrate Scope
Next, we assessed the substrate scope. We used the best enzyme in the initial
screening, L7-FL and tested a range of substrates including secondary amines,
primary amines, and aliphatic amines (Figure 4.6).
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Figure 4.6: The substrate scope of the N–H insertion reaction using L7-FL. Re-
actions were set at 10 mM substrate loading using whole-cell E. coli. TTN was
determined by protein concentration and HPLC data.
We assessed the yield and selectivity in formation of generalized product 4.4a. Both
secondary anilines (4.4b-4.4g, 4.4q), and primary anilines (4.4h-4.4p) showed high
yield and selectivity across the board. Yields were as high as 99% (4.4d, 4.4f),
and selectivity of up to 98% ee was also observed (4.4b, 4.4c). Substrates with
substituents on the ring including fluoro (4.4e) and methyl (4.4c and 4.4d) were well
tolerated, as were heterocycles (4.4f, 4.4g) despite their bulk. In addition, an ethyl
group on the amine (4.4b) does not affect the efficacy of the enzyme. Indeed, methyl
substituents on the ring, did not negatively affect the selectivity or yield, no matter
the position. For instance, 4.4m is sterically hindered and bears two ortho-methyl
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substituents, yet it achieves 1040 TTN and 90% ee. Interestingly, the unsubstituted
aniline (4.4h) had the lowest enantiomeric excess (50% ee).
Finally, we wanted to test our enzyme with substrates with amines attached to
sp3 hybridized carbons. Aliphatic amines make enantioselective N–H insertion
challenging due to the increased basicity of the substrate, and reactions of this
nature were recently demonstrated by copper catalysts in 2019.57 Our enzymes
could catalyze these reactions with both primary (4.4n-p) and secondary (4.4q)
aliphatic amines with high ee and yield. All of the primary amines had selectivity
above 85% ee, though the secondary amine only displayed 66% ee. With this
promising start, we predict that with further evolution, we may be able to expand
this platform beyond homobenzylic amines and perhaps tolerate aliphatic amines
without proximal aromatic systems, though this remains a challenge for biocatalysts.
Curious about the properties of other enzymes in the lineage bearing the A264S,
particularly L6 and L7, we then compared the properties of L6, L7, and L7-FL
for a subset of substrates. We wanted to assess whether the superiority of L7-FL
identified in the model reaction held true for other substrates (Figure 4.7).
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Figure 4.7: A bar graph comparing L6 (blue), L7 (orange), and L7-FL (green) for
five substrates (labels in Figure 4.6). L7-FL shows highest ee for most substrates
tested, including the model substrate. Figure made using Holoviews with a Bokeh
backend.
Indeed, L7-FL performed with higher enantiomeric excess than L7 and L6 for all
substrates tested except 4.4d. We are unsure why the addition of the FAD domain
decreases the enantioselectivity of 4.4d Nevertheless, L7-FL appears to have the
most favorable overall selectivity profile, so we decided to focus on it and test its
limits.
4.3 Large-Scale Reactions
We turned our attention to large scale reactions (Figure 4.8). We synthesized 4.4d
on a gram scale with 97% yield and 96% ee. We also synthesized 4.4e and 4.4l
at a 1-mmol scale with 97% and 86% yield, respectively. We then synthesized
4.4m on a mmol scale, which was then applied to the formal synthesis of (S)-
ofurace, a fungicide.58 This demonstrates an application of this technology. By
X-ray crystallography, carried out by Dr. Zhen Liu, we determined the (S) absolute
configuration for these products.
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Figure 4.8: The application of our enzymes in large scale synthesis. This demon-
strates that our enzymes remain effective on a preparative scale. The products are all
formed with more than 2700 TTN, more than 70% yield. The ee is consistent with
the analytical scale reactions. Product 4.4m can be extended to the formal synthesis
of (S)-orfurace, a fungicide.
4.4 Conclusion
While enantioselective N–H insertion is a challenge, we demonstrated thatL7-FL is
able to obtain 95% ee and >92% yield for the model reaction. L7-FL was tested on
diverse substrates, including heterocycles and homobenzylic amines. Across these
substrates, L7-FL has good to excellent yield (from 40 to >99%) and consistently
high enantioselectivity (from 50% to 98% ee).Furthermore, L7-FL has shown to
be scalable with preparative scale reactions. This further expands the growing
repertoire of biocatalysts in asymmetric catalysis and could potentially provide an
environmentally friendly approach to the synthesis of important chiral U-amino
lactones.
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C h a p t e r 5
CONCLUSIONS AND FUTURE DIRECTIONS
We have expanded nature’s chemical repertoire by creating biocatalytic methods
to form bonds between a biologically privileged lactone into second period atoms.
We leveraged the precise three-dimensional, active sites of enzymes to achieve high
yield and enantioselectivity, even in products with contiguous chiral centers. We
hope our enantioselective enzymatic methods for lactone insertion will be used in
more environmentally friendly, cost-efficient, and sustainable synthesis of chemical
targets.
Furthermore, this set of work has demonstrated an instance where evolved enzymes
have shown impressive flexibility. We demonstrated that the same enzymatic lineage
(P450-L) could catalyze both enantioselectiveC–HandN–H insertion reactionswith
excellent yields and selectivity. This goes against the notion that enzymes are only
capable of an extremely limited set of reactions. This provides a good outlook for a
future where many diverse industrial chemical reactions are achieved by enzymes.
To build upon this work, we are interested in expanding our biocatalytic platforms
to include more diverse substrates, including lactones of different sizes, and B–H,
C–H, and N–H bonds with different electronic environments. We are also interested
in better characterizing the precise mechanism of these lactone insertion reactions
because this could provide valuable insights into enzymatic processes. Finally, we
are searching for specific complex chemical targets that we may apply our enzymes
toward, as we continue moving engineered biocatalysts out of the lab and into the
world.
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C h a p t e r 6
SUPPORTING INFORMATION
6.1 Main Methods
Synthesis of 5-memberd Lactone Carbene Precursor (2.2)
A mixture of sodium azide (4.83g, 4eq), sodium hydroxide solution (80 mL, 3.875
M), hexane (80 mL), and tetrabutylammonium bromide (60 mg, 0.1 eq) were cooled
on an ice bath. Trifluoromethanesulfonic anhydride (6.20mL, 2 eq) was added drop-
wise in a reaction vesicle exposed to air. After 10 minutes, 2-acetyl-butyrolactone
(2 mL, in 80 mL ACN) was added, and the reaction quickly turned yellow. After
30 minutes, the organic layer was extracted using a separatory funnel, dried with
sodium sulfate, filtered, and concentrated. The product was then purified by a silica
gel column. The purity of the product was confirmed by TLC and the product was
vacuumed to yield a yellow-orange solid.
Synthesis of 6-membered Lactone Carbene Precursor
A round bottom flask was dried, put under N2, and charged with diisopropyl amine
(13.41 mmol, 1.88 mL). THF (anhydrous, 40 mL) was added and the flask was
placed on ice. When cooled, a solution of n-butyllithium (13.4 mmol, 5.36 mL,
2.5 M, in hexanes) was added. Using a magnetic stir bar, the solution was stirred
and cooled to -78 °C. tetrahydro-2H-pyran-2-one (11.2 mmol, in 27 mL THF)
was added dropwise and the reaction was stirred (15 min, -78°C). Finally, 2,2,2-
trifluoroethyl trifluoroacetate (16.8 mmol, 2.4 mL) was added dropwise and the
reaction was stirred (-78 °C, 30 minutes). The reaction was quenched with HCl (50
mL, 10%). Following extraction (diethyl ether, 50 mL, three times) and washing of
the organic layer (brine), the crude product was dried (Mg2SO4) and concentrated
under vacuum. In the next step, the product was then dissolved in CH2Cl2 and
f-NBSA (14.1 mmol, 3.21 g) and DBU (2.39 mL, 16 mmol) were added. After
stirring for 30 minutes (at room temperature), the product was quenched with water
(50 mL). The product was extracted (diethyl ether, 40 mL, seven times). Following
a wash with brine, the product was dried (Mg2SO4) and concentrated by vacuum.
The product was purified using a silica column. Product identity was confirmed by
TLC.
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Synthesis of Authentic Standards (B–H Insertion)
To a solution of NHC-borane (1 equiv.), Rh2(OAc)4(2 mol%) was added. The diazo
(1.2 equiv) was added through a syringe pump (addition over 2 h). After stirring
(overnight), the product was concentrated and purified by silica chromatography.
Synthesis of Authentic Standards (N–H Insertion)
U-Bromo-W-butyrolactone (330 mg, 0.185 mL, 2 mmol, 1 equiv), the aryl amine
(2.5 mmol, 1.25 equiv.), and DMF (1.5 mL) were added to a vial. The reaction was
stirred for 24 h (at 80 °C).
Saturation Mutagenesis
Single-site saturation mutagenesis libraries were constructed by a 22-codon trick
protocol.41 PCR products were DpnI digested. The fragments were purified by gel
electrophoresis on either a 1% or 2% agarose gel, depending on the length of the
DNA, followed by the Zymoclean™ DNA recovery protocol. A Gibson assembly
protocol59 was then performed on the fragments and the pET22b (+) backbone for
ligation. These plasmid libraries were stored at -20°C.
Transformation
After cloning, electrocompetent cells (BL21 E. cloni®, Lucigen) were transformed
with the plasmid libraries via electroporation. After shocking the cells, they were
allowed to recover in SOC at 37 °C for 45 min. The cells were then spread on agar
plates containing LB and ampicillin and allowed to incubate for 16 hours at 37 °C.
Single colonies were picked for overnight cultures using sterilized toothpicks.
Glycerol Stock Preparation
Overnight cultures of E. coli harboring hemeprotein variants in LBAmp were mixed
with 50% glycerol solution (1:1) and stored at -78 °C.
DNA Extraction (Using QIAPrep Kit)
Overnight cultures of the hemeprotein variants were resuspended in buffer P1. Lysis
buffer (250 `L) was added followed by neutralization buffer (350 `L). The mixture
was then centrifuged (10 mins, 14000 × g), and the supernatant was added to a
spin column. The suspension was centrifuged again (14000 × g, 1 min), and the
flow through was discarded. Wash buffer (750 `L) was added to the column and
centrifuged (14000 × g, 1 min). The flow through was discarded, and the column
was transferred to a new vial. Elution buffer (50 `L) was added, and the solution
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was centrifuged (14000× g, 1 min). The plasmid DNA-containing eluate was stored
at -20 °C, and an aliquot was sequenced.
Protein Expression (P411 Variants)
Overnight cultures of E. coli expressing the evolved P411 variants in LBAmp grown
at 37 °C for 15–18 hours (220 rpm) in a 96-well plate. Preculture (50 `L) was added
to Hyper Broth supplemented with ampicillin (HBAmp, 950 `L) for inoculation and
was then allowed to grow for 2.5 hours (37 °C, 220 rpm, 80% relative humidity). The
cells were then induced for expression by addition of 5-aminolevulinic acid (5-ALA,
1.0 mM, final concentration) and isopropyl V-d-1-thiogalactopyranoside (IPTG, 0.5
mM, final concentration) after being cooled on ice for 45 minutes. Protein variants
were expressed at 20 °C for 22 h and 220 rpm.
Reaction Setup (Plates)
E. coli in 96-well plates expressing protein variants were pelleted via centrifuge
(4500 × g, 5 minutes, 4 °C). The supernatant was decanted, and the cells were
resuspended in M9-N buffer (340 `L). d-glucose solution (40 `L, 250 mM) was
added to the cell suspension (340 `L). The plateswere then brought into an anaerobic
chamber, where each substrate (10 `L, 400 mM in ethanol) was added. The plates
were allowed to shake in the anaerobic chamber for 12 h.
Reaction Analysis (Reverse Phase HPLC)
Internal standard (20 `L of 20 mM solution of phenethyl acetate, ?-methyl-anisole,
allyl phenyl ether, or 1,3,5-trimethoxy-benzene) and ACN (580 `L) were added to
each well in the plate. The internal standard selection is substrate-dependent and is
chosen to avoid overlap with any peaks. The plate was vortexed and centrifuged.
The supernatant was then filtered through centrifuge filtration. The resulting filtrate
was analyzed on the HPLC using a developed method (C18-Kromasil column, 40%
water, 60% ACN, 1.2 ml/min) that results in unique and discrete peaks.
Protein Expression (P411, Validation)
Overnight cultures of E. coli harboring a desired P411 variant were set up in LBAmp
(6 mL) and grown at 37 °C for 15-18 hours (250 rpm). Five mL of preculture were
added to HBAmp (45 mL, with ampicillin and d-glucose) and shaken at 37 °C for
2.5 h). The cultures were cooled on ice for 45 minutes and 5-aminolevulinic acid
(5-ALA, 1.0 mM final concentration) and V-d-1-thiogalactopyranoside (IPTG,0.5
mM final concentration) were added. Protein variants were expressed at 20 °C for
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22 h (140 rpm).
Protein Expression (Cytochrome c, Validation)
Overnight cultures of E. coli harboring a desired cytochrome c variant were set up
in LBchlor (5 mL) and grown at 37 °C for 15-18 hours (250 rpm). Preculture (0.5
mL) was added to HBchlor (25 mL, treated with ampicillin and glucose) and shaken
(37 °C, 3h). The cultures were cooled on ice for 45 minutes and 5-aminolevulinic
acid (5-ALA) and V-d-1-thiogalactopyranoside (IPTG) were added (200 `M and
20 `M final concentration). Protein variants were expressed at 20 °C for 22 h (160
rpm).
Reaction Setup (Validation)
The cultures were centrifuged (4500 × g, 5 minutes, 4 °C). The supernatant was
decanted, and the cells were resuspended in M9-N buffer such that an OD600= 60
was achieved. To vials, cell suspension (340 `L) and d-glucose (40 `L, 250 mM)
were added. Substrates (10 `L, 400 mM in ethanol) were added to the vials in
an anaerobic chamber, then the vials were sealed and allowed to shake for 12 h.
Replicates were worked up for HPLC analysis (detailed above) or worked up with
1:1 hexane : ethyl acetate for chiral HPLC analysis.
Reaction Analysis (Chiral HPLC)
1:1 Hexane : ethyl acetate (1 mL) was added to each reaction vial. After cells were
vortexed and centrifuged (4500 × g, 5 minutes), the organic phase was transferred to
glass vials. The solventwas removed by rotary evaporation, and the dichloromethane
(200 `L) was added to each reaction vial. Using synthesized authentic standards,
chiral HPLC methods were developed that allowed for discrete peaks for both
enantiomers. Using these methods, the enantiomeric excess of the reactions was
assessed.
Hemochrome Assay
Aliquots of an OD600=60 cell suspension (3 mL) were added to 15-mL tubes and
lysed by sonication (2 minutes, 1 second on/ 1 second off, two times). The lysed
cells were then transferred to Eppendorf tubes and centrifuged (20,000 × g„ 4 °C,
10 minutes). The supernatant was transferred to a glass vial. Then, a solution of
NaOH/pyridine/K3Fe(CN)6 (500 `L) was mixed with the lysate (500 `L) and the
UV absorbance was assessed (380 nm – 650 nm). Then, a solution of dithionite (5
`L) was added and the UV absorbance was assessed again (reduced spectrum).
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Enzymatic Synthesis of Authentic Standards (C–H Insertion)
The desired protein was expressed as described above, using larger quantities (250
`L HBAmp). The cells were centrifuged (4500 × g, 5 minutes, and 4 °C) and
resuspended in M9-N buffer such that an OD600=60 was achieved. To 50-mL
Falcon tubes, cell suspension (30 mL) was added followed by d-glucose solution
(3 mL). In an anaerobic chamber, substrates (1.25 mL, 400 mM in ethanol) were
added. The tubes were shaken in the anaerobic chamber for 12 h. The cells were
then treated with 1:1 hexane : ethyl acetate (15 mL) and centrifuged (5000 × g, 10
minutes, room temperature). The organic phase was separated. This process was
repeated four times. The organic phase was dried by magnesium sulfate. Following
filtration, the products were isolated by silica gel chromatography.
Calibration Curves
A stock solution of the purified product (500 `L, 100 mM) was prepared. Vials
containing 0.6mL acetonitrile, 0.4mLH2O, and 20 `L of a desired internal standard
were prepared. Incrementing amounts of the stock solution were added to vials (4
`L, 8 `L, 16 `L, 24 `L, 32 `L, 40 `L) in duplicate. These vials were than assayed
by HPLC and a calibration curve was developed.
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